Phostine 3.1a as a pharmacological compound with antiangiogenic properties against diseases with excess vascularization.
Bousseau S, Marchand M, Soleti R, Vergori L, Hilairet G, Recoquillon S, Le Mao M, Gueguen N, Khiati S, Clarion L, Bakalara N, Martinez MC, Germain S, Lenaers G, Andriantsitohaina R.
Bousseau S, et al.
FASEB J. 2019 May;33(5):5864-5875. doi: 10.1096/fj.201801450RRR. Epub 2019 Feb 28.
FASEB J. 2019.
PMID: 30817178
Free article.
Thus, these data show that use of PST 3.1a is an innovative approach to target angiogenesis.-Bousseau, S., Marchand, M., Soleti, R., Vergori, L., Hilairet, G., Recoquillon, S., Le Mao, M., Gueguen, N., Khiati, S., Clarion, L., Bakalara, N., Martinez, M …
Thus, these data show that use of PST 3.1a is an innovative approach to target angiogenesis.-Bousseau, S., Marchand, M., Soleti …